A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Advanced Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 375 (planned)
- Started
- Aug 27, 2025
- Main results expected
- Nov 2027
- Fully finished
- Aug 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Parts A and C - Occurrence of dose limiting toxicities (DLTs) within a participant during the DLT observation period
Measured over: Up to 28 days after first dose of investigational medicinal product (IMP).
All parts - Percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs by relationship
Measured over: From the time of the first dose of IMP until 90 days after the last dose of IMP, approximately up to 31 months.
Parts A and C - Percentage of participants with dose interruptions or discontinuations of study treatment due to TEAEs
Measured over: From the time of the first until last dose of IMP, approximately up to 31 months.
Parts B and D - Percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEs
Measured over: From the time of the first until last dose of IMP, approximately up to 31 months.
Parts B and D (expansion cohorts) - Objective response rate (ORR)
Measured over: From first dose of IMP until end of study, approximately up to 31 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07147348 · record last updated 2026-06-15 · checked 2026-11-09 15:47 UTC